To include your compound in the COVID-19 Resource Center, submit it here.

StaphVax: Phase III

NABI began a U.S. Phase III trial of StaphVax in 3,000 end stage renal disease (ESRD)

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE